

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number  
**WO 2004/007677 A2**

- (51) International Patent Classification<sup>7</sup>: **C12N**
- (21) International Application Number:  
PCT/US2003/021875
- (22) International Filing Date: 11 July 2003 (11.07.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/395,081 11 July 2002 (11.07.2002) US
- (71) Applicant (for all designated States except US): **THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION** [US/US]; 1960 Kenny Road, Columbus, OH 43210-1063 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **HENKIN, Tina, M.**

[US/US]; 287 Monsarrat Drive, Dublin, OH 43017 (US).  
**GRUNDY, Frank, J.** [US/US]; 287 Monsarrat Drive, Dublin, OH 43017 (US).


(74) Agent: **DOBREA, Diane, H.**; Calfee, Halter & Griswold LLP, Suite 1400, 800 Superior Avenue, Cleveland, OH 44114 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

[Continued on next page]

(54) Title: IN VITRO TRANSCRIPTION ASSAY FOR T BOX ANTITERMINATION SYSTEM



(57) Abstract: A method and assay system is provided for screening for antimicrobial agents that inhibit or otherwise disrupt the transcription of bacterial aminoacyl-tRNA synthetases, particularly those in Gram-positive bacteria. The method and assay utilizes purified RNA polymerase, isolated, for example, from either *Bacillus subtilis* or *Escherichia coli*, and a template DNA fragment which encodes glycyl-tRNA synthetase, containing the promoter and leader region of the *B. subtilis* *glyQS* gene, including the T-Box terminator/antiterminator. Incubation in the presence of nucleotide triphosphates results in synthesis of an RNA transcript initiating at the *glyQS* promoter and terminating at the leader region terminator. Read-through of the terminator, and synthesis of an extended transcript, is dependent on addition of purified glycyl-tRNA. The method and assay is dependent on the use of the specified tRNA species; non-specific tRNA fails to stimulate antitermination. The assay can be used to screen for inhibitors that specifically inhibit the T-box antitermination mechanism.



ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declaration under Rule 4.17:**

— of inventorship (Rule 4.17(iv)) for US only

**Published:**

— without international search report and to be republished  
upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**IN VITRO TRANSCRIPTION ASSAY FOR T BOX ANTITERMINATION SYSTEM****CROSS REFERENCE TO RELATED APPLICATIONS**

This application claims the benefit of the filing date of U.S. Provisional Application No. 60/395,081, filed July 11, 2002, which is incorporated herein by reference in its entirety.

**STATEMENT ON GOVERNMENT FUNDED RESEARCH**

5           The present invention was made, at least in part, with support from the National Institutes of Health Grant GM47823. The United States Government has certain rights in the invention.

**BACKGROUND**

10           Aminoacyl-tRNA synthetases are enzymes found in all bacteria, plants and animals, and are required for cells to make protein. Bacterial aminoacyl-tRNA synthetases are usually present as a single species for each amino acid; approximately 20 different synthetases are required for aminoacylation. Lacking redundancy in the aminoacylation step of protein synthesis, bacteria are critically dependent on the transcription and translation of each of these enzymes. Inhibitors that block the production or function of one or more bacterial synthetases are therefore potentially useful as antimicrobial agents for prevention and treatment of disease in humans and other organisms.

15           A potential target for shutting-down expression of bacterial aminoacyl synthetase genes is the T-box termination/antitermination transcriptional control complex. Many Gram positive, and certain Gram negative bacteria have genes that are regulated by a transcriptional control element known as the T-box termination/antitermination complex. This complex comprises a set of specific control elements that are found within the leader sequences located upstream of certain bacterial genes. The structural arrangement of these leaders is conserved across a broad spectrum of bacterial strains, and the control elements that are specific to the T-box termination/antitermination complex are highly conserved. The T-box termination/antitermination complex regulates expression of aminoacyl-tRNA synthetase genes and other amino acid-related genes in response to the level of charging of cognate tRNAs. Uncharged tRNAs permit read-through of the template by favoring the antiterminator configuration, thus resulting in expression of the gene located downstream of the leader region.. Charged tRNAs block read-through of the template by favoring the terminator configuration, thus resulting in termination of expression. Since expression of these T-box regulated genes is required for survival of the bacterial cell, and this system is found in many pathogenic organisms, the T box system represents a target for antimicrobial agents. To date, it has not been possible to

isolate this complex in a cell-free system in order to evaluate potential specific modulators or inhibitors of expression of T-box regulated genes. Thus, it would be useful to have a well-defined *in vitro* assay that would permit evaluation of agents that specifically interact with the T-box termination/antitermination complex. Such an assay system would permit the rapid and high throughput screening of potential inhibitors of expression of T-box regulated genes.

## SUMMARY

An *in vitro* screening assay is provided for identifying inhibitors of transcription of T-box regulated genes. An *in vitro* transcription assay system is also provided and comprises a template DNA (comprising a bacterial promoter, a leader region of a T-box-regulated gene (such as the *B. subtilis* *glyQS* gene), and a downstream portion), a cognate tRNA which is specific for the specifier sequence of the template DNA (such as *B. subtilis* tRNA<sup>Gly</sup>), and bacterial RNA polymerase. Combining a test agent with the assay system permits the detection of potential inhibitors which function to block antitermination in the T-box region, and thus cause termination of transcription and loss of expression of T-box regulated genes.

The screening assay comprises the steps of: (a) incubating template DNA and cognate tRNA, RNA polymerase, a divalent metal cation, such as magnesium (Mg<sup>2+</sup>), nucleoside triphosphates (singularly referred to as "NTP," including adenosine triphosphate, or ATP, guanosine triphosphate, or GTP, cytosine triphosphate, or CTP, and uridine triphosphate, or UTP), and a dinucleotide which corresponds to the dinucleotide encoded by the transcription start site in the leader, such as ApU, ApC, etc., both with and without a test agent which is a potential inhibitor; (b) assaying for mRNA transcription in the system; and (c) comparing the results obtained in the absence versus the presence of the test agent.

The screening assay is useful for rapid, high volume screening of substances that inhibit T-box regulated antitermination of transcription in bacteria which rely upon the T-box control mechanism, and more particularly in Gram-positive bacteria. This inhibition effectively terminates transcription of T-box regulated genes, such as glycyl-tRNA synthetase, restricting the availability of the gene product and thereby interrupting bacterial protein production and bacterial viability. In addition to inhibition of T-box regulated genes such as glycyl- and other aminoacyl-tRNA synthetases, such inhibitors may also inhibit expression of other T-box regulated genes. The identified inhibitors would be useful agents for applications where antimicrobials are desired, such as in the treatment of bacterial infections and related disease in humans and other affected organisms. Thus, the screening assay is useful for identifying potential antimicrobial agents, including antibiotics.

## BRIEF DESCRIPTION OF THE DRAWINGS

**FIG. 1** shows a secondary structure model of the *B. subtilis glyQS* leader RNA encoded by a template DNA. Sequence is shown from the transcription start site (+1) through the end of the leader region terminator; the alternate antiterminator is shown to the right of the terminator. The structure is based on the co-variation model of T box family leaders (2, 5). Major conserved features are labeled, and conserved primary sequence elements are denoted with asterisks. The specifier sequence residues are boxed. The *glyQS* sequence was obtained from the *B. subtilis* genome sequence (11); Sequencing of this region of DNA from strain BR151MA revealed a substitution of A for U at position +6. The residues in brackets (residues 113–122) are replaced by the Stem II and IIA/B elements in most T box family leaders, including *B. subtilis tyrS*.

**FIG. 2** shows a secondary structure model of the *B. subtilis tyrS* leader RNA. Sequence is shown from the transcription start site through the end of the leader region terminator; the alternate antiterminator is shown to the right of the terminator. Major conserved features are labeled, and conserved primary sequence elements are denoted with asterisks. The specifier sequence residues are boxed. The *tyrS* sequence was obtained from the *B. subtilis* genome sequence (11); the Stem II element is common to most T box family leaders, except *glyQS* genes.

**FIG. 3** shows a structure-based alignment of *glyQS* leaders, including the T-box sequence, from several bacterial strains; the *B. subtilis tyrS* leader is shown at the top, for comparison. The sequences are aligned based on major domains, as follows: Panel A: 5' side of Stem I; Panel B: 3' side of Stem I; Panel C: Stem II (replaced by an unpaired stretch in most of the *glyQS* leaders); Panel D: Stem IIA/B (missing in most of the *glyQS* leaders); Panel E: Stem III; Panel F: antiterminator. The specifier in each sequence is indicated in bold (TAC for *tyrS* and GGC for *glyQS*). (Key: B. sub: *Bacillus subtilis*; B. ant: *Bacillus anthracis*; B. cer: *Bacillus cereus*; B. hal: *Bacillus halodurans*; C. ace: *Clostridium acetobutylicum*; C. hyd: *Carboxydotherrmus hydrogenofomans*; D. rad: *Deinococcus radiodurans*; E. fae: *Enterococcus faecalis*; L. lac: *Lactococcus lactis*; L. mon: *Listeria monocytogenes*; S. aur: *Staphylococcus aureus*; S. equ: *Streptococcus equi*; S. mut: *Streptococcus mutans*; S. pne: *Streptococcus pneumoniae*; and S. pyo: *Streptococcus pyogenes*).

The dashes represent spaces inserted to permit alignment of all of the T box leaders (not just *tyrS/glyQS*); the leaders are variable in having helical domains of different lengths, and insertions/deletions/replacements at various positions, however, the overall pattern is highly conserved. The alignments start at the 5' side of the base of Stem I; the distance from the transcription start-site is variable, but is usually around 20-30 nt. In some cases, the T box

structure is embedded within a larger transcriptional unit, so that the 5' portion of the mRNA is constitutively transcribed and the gene encoded is constitutively expressed; in those cases, the T box element controls expression of the 3' transcriptional units. Accordingly, there are no specific requirements as to how much sequence is upstream of the structural array shown in the alignment.

**FIG. 4** is a list of bacterial strains in which T-box regulated genes have been identified.

**FIG. 5** shows a model of the T box antitermination mechanism actuated by a cognate uncharged tRNA. When the cognate tRNA is efficiently charged, read-through is blocked by formation of the terminator helix. When the cognate tRNA is not efficiently charged, read-through is permitted by formation of the antiterminator structure.

**FIG. 6** shows a model of interaction of a T-box leader in the antiterminator conformation with a cognate uncharged tRNA.

**FIG. 7** shows a model of the T box antitermination mechanism. The arrow indicates the transcription initiation site. The black rectangle represents the coding region of the regulated gene. Uncharged tRNA is postulated to interact with the nascent transcript at both the specifier sequence (a codon specific for the target gene) and the antiterminator bulge, stabilizing the antiterminator and preventing formation of the competing terminator structure. RNA polymerase (RNAP) then continues past the terminator region, and the full-length transcript is synthesized. "Factor?" indicates putative factor(s) that could modulate the leader RNA-tRNA interaction *in vivo*.

**FIG. 8** shows the *glyQS* promoter region map.

**FIG. 9** shows results of *in vitro* transcription of the *glyQS* and *tyrS* leader regions. Lanes 1–5, *glyQS* DNA; lanes 6–11, *tyrS* DNA. Lanes 1, 3, and 6, no tRNA added; lanes 2, 4, and 7, tRNA<sup>Gly</sup> (T7 transcript); lanes 5, 8, and 11, tRNA<sup>Tyr</sup> (T7 transcript); lane 9, *E. coli* tRNA<sup>Tyr</sup> (modified, purchased from Sigma); lanes 3–9, NusA added; lanes 1, 2, 10, and 11, no NusA. T = terminated transcript; RT = read-through transcript. Percent read-through is indicated at the bottom of each lane.

**FIG. 10** shows specificity of the *glyQS*-tRNA<sup>Gly</sup> interaction. (A) Interaction of the *glyQS* leader in the antiterminator conformation with tRNA<sup>Gly</sup>. Substitutions at the specifier sequence and antiterminator regions of the leader, and at the anticodon and acceptor end of the tRNA, are shown with arrows. (B–E) show *in vitro* transcription reactions using different combinations of variants of *glyQS* templates and tRNA<sup>Gly</sup>. (B) Wild-type *glyQS* template DNA (GGC specifier

sequence, A158 antiterminator). (C) *glyQS*-UGC template DNA (cysteine specifier sequence, A158 antiterminator). (D) *glyQS*-A1583U template DNA (GGC specifier, U158 antiterminator). (E) *glyQS*-UGC/A1583U template DNA (cysteine specifier sequence, U158 antiterminator). Lane 1, no tRNA; lane 2, wild-type tRNA<sup>Gly</sup> (GCC anticodon, U73 discriminator); lane 3, tRNA<sup>Gly</sup>-GCA (GCA anticodon, U73 discriminator); lane 4, tRNA<sup>Gly</sup>-U733A (GCC anticodon, A73 discriminator); lane 5, tRNA<sup>Gly</sup>-GCA/U733A (GCA anticodon, A73 discriminator). T, terminated transcript; RT, read-through transcript. Percent read-through is indicated at the bottom of each lane.

**FIG. 11** shows the polynucleotide sequence for the *glyQS* gene from *Bacillus subtilis* corresponding to the *in vitro* transcription template: from B. subtilis 168 (obtained from SubtiList Web site).

**FIG. 12** shows the polynucleotide sequence for the *glyQS* DNA template from *Bacillus subtilis* strain BR151MA, a 440 nucleotide fragment that corresponds to the gene sequence from 135 nucleotides upstream of the *glyQS* transcription start site to nucleotide position 305 of the transcript; the termination site is predicted to be around position 220.

**FIG. 13** shows the tRNA<sup>Gly</sup> DNA sequence: (from SubtiList, confirmed by sequencing of this region in BR151MA).

**FIG. 14** shows the PCR primers used for preparing *glyQS* and *tyrS* templates for *in vitro* transcription:

**FIG. 15** shows the polynucleotide sequence for the *tyrS* template sequence (for strain 168 per SubtiList website and confirmed for strain BR151MA).

**FIG. 16** shows the polynucleotide sequences for the oligonucleotide primers used to generate the tRNA<sup>Gly</sup> and tRNA<sup>Tyr</sup>.

**FIG. 17** shows the tRNA<sup>Tyr</sup> DNA sequence (from SubtiList, confirmed by sequencing of this region in BR151MA).

## DETAILED DESCRIPTION

The present invention relates to a new assay procedure and system for identifying substances which inhibit the transcription of aminoacyl-tRNA synthetases, particularly in Gram-positive bacteria. The assay can be used to screen for inhibitors that specifically inhibit the T-box antitermination mechanism. Such substances would be useful as antimicrobials, such as, for example, antibiotics.

### Definitions

“Antitermination,” as used herein, refers to the mechanism by which a T-box termination/antitermination complex is affected to permit read-through of the terminator sequence on the nascent mRNA, and thus permit full transcription of the encoded mRNA.

“Antiterminator,” as used herein, refers to the sequence in the nascent mRNA (and its complimentary DNA) that functions in the T-box termination/antitermination complex to permit read-through of the terminator sequence on the nascent mRNA, and thus permit full transcription of the encoded mRNA.

“Divalent metal cation,” as used herein, refers to the species of metal cations that are useful components of *in vitro* transcription assay systems, and include magnesium ( $Mg^{2+}$ ).

“Effector,” as used herein, refers to a transcription component, such as a tRNA, which affects or actuates the T-box terminator/antiterminator complex.

“*glyQS*,” as used herein, refers to either a DNA molecule which comprises all or a portion of a bacterial *glyQS* gene, including the promoter and leader regions, and optionally all or a portion of the polynucleotide coding sequence encoding a wild-type or variant bacterial glycyl-tRNA synthetase, or an mRNA product encoded by the same.

“Gram positive bacteria,” as used herein, means the phylogenetic group of bacteria commonly known as and referred to as the Gram-positive branch.

“Leader,” as used herein, refers to a wild-type or variant form of the upstream portion of a bacterial gene, particularly a bacterial gene which is regulated by a T-box termination/antitermination complex, and which comprises the elements of a T-box termination/antitermination complex, including a specifier sequence, a T-box, and conserved terminator and antiterminator consensus motifs. Variants comprise modifications to one or both of the specifier and T-box sequences, wherein modifications to either are made to alter the specificity for a cognate tRNA such that the modified specifier and T-box sequences recognize a different tRNA than is recognized by the wild-type specifier and T-box sequences.

“Halted-complex transcription assay system,” as used herein, refers to an *in vitro* transcription assay system in which one of the four nucleoside triphosphates required for complete RNA synthesis is excluded from the initial incubation conditions, resulting in the temporary stalling of the RNA polymerase transcriptional complex at a particular location on the template DNA; in the case of transcription of *glyQS*, omission of CTP (cytosine triphosphate) results in an arrest in transcription prior to incorporation of the residue at position +17 (the first cytosine residue in the *glyQS* nascent RNA encoded by the template DNA). The halted-complex system is useful to



permit transcription initiation and transcription elongation to be carried out under different conditions or with different reaction components. Transcription is initiated under a first set of conditions in the absence of one of the four NTPs; subsequently, transcription elongation is carried out under a second set of conditions upon the addition of excluded NTP.

5 “Inhibitor,” as used herein, refers to a substance which in any way interferes with antitermination so as to effectively block the transcription of a bacterial gene that is regulated by the T-box mechanism, such as a bacterial aminoacyl-tRNA synthetase gene. Substances which are identified using the disclosed screening methods may be used as inhibitors of transcription of such genes to block production of the gene product in bacterial cells. Such inhibitors may thus  
10 be useful as antimicrobials. The inhibitors may be added to foodstuffs, or other products such as cosmetics. The inhibitors may be useful for the treatment of plants to prevent the proliferation of infective organisms. The inhibitors may also be useful as treatment or prophylactics in animals, particularly humans.

“mRNA read-through product,” as used herein, refers to the mRNA product which includes the  
15 leader sequence and a portion of mRNA that is downstream from the leader sequence, which is encoded by a template DNA.

“Promoter,” as used herein, refers to a DNA sequence that allows efficient recognition and transcription initiation by bacterial RNA polymerase (RNAP); examples include the *B. subtilis* *glyQS* promoter, and the *B. subtilis* *rpsD* promoter, which allow high level transcription (are  
20 efficiently recognized by a bacterial RNA polymerase complex).

“Read-through,” as used herein, refers to the process by which the RNA polymerase transcriptional complex proceeds through the leader sequence to produce an mRNA transcript of the aminoacyl-tRNA synthetase. In the context of the T-box control mechanism, read-through is a result of successful antitermination; read-through does not occur if antitermination is inhibited  
25 or otherwise unsuccessful.

“Specifier,” as used herein, refers to the specific tri-nucleotide sequence in a polynucleotide sequence comprising the upstream untranslated region of a gene encoding a bacterial aminoacyl-tRNA synthetase; the specifier sequence is specific for and interacts with the cognate tRNA anticodon.

30 “Template DNA,” as used herein, refers to the polynucleotide used according to the inventions hereof which encodes all or a fragment of a T-box-regulated gene, such as the *Bacillus subtilis* glycyl-tRNA synthetase gene, and comprises, in order from the 5' to the 3' end: (i) a bacterial promoter; (ii) a leader comprising all or part of a leader, as defined herein, including a

transcription initiation site; and (iii) a downstream polynucleotide of sufficient length for detection of a read-through mRNA product, located downstream of the leader region terminator. The downstream portion may vary from 30 to over 100 nucleotide residues, and may be approximately 30 or more nucleotide residues.

- 5 “Terminator,” as used herein, refers to the sequence in the nascent mRNA (and its complimentary DNA) that functions in the T-box termination/antitermination complex to halt transcription of the encoded mRNA.

“RNA polymerase” (RNAP), as used herein, refers to an enzyme complex isolated from a bacterial species (either *B. subtilis* or *E. coli* have been tested in this system) that is capable of  
10 recognizing the promoter region on the test DNA template and exhibits efficient termination at the T box leader terminator during transcription in the absence of tRNA, and efficient tRNA-directed read-through of the leader region terminator when the appropriate tRNA is present in the incubation mixture.

“tRNA” as used herein refers to purified RNA generated by *in vitro* transcription using T7  
15 RNAP, using a template DNA designed so that the transcription product is identical in sequence to tRNA<sup>Gly</sup>.

#### The T-Box family of genes and T-box transcription control

The T box transcription termination control system is widely used in Gram-positive bacteria to regulate expression of aminoacyl-tRNA synthetase, amino acid biosynthesis, and  
20 transporter genes (1). Genes in the T box family contain a set of conserved elements in the leader region of the mRNA. The transcripts of genes regulated by this mechanism contain a 200- to 300-nucleotide un-translated leader that includes a factor-independent (intrinsic) transcription termination signal and a competing antiterminator structure (2). FIGS. 1 and 2, respectively, show secondary structure models of the *glyQS* and *tyrS* leaders from *Bacillus subtilis*. FIG. 3  
25 shows the aligned sequences for the *glyS* leader from sixteen different bacterial strains, as well as the *tyrS* leader from one bacterial strain. FIG. 4 shows a list of organisms in which T-box family genes have been identified. These include primarily Gram-positive bacteria, as well as some other non-Gram-positive bacterial strains. Not all of these organisms have *glyQS* under this regulatory system, but all of the organisms listed have at least one gene with a T box leader. Of  
30 this group, the most important pathogens are *Bacillus anthracis*, *Mycobacterium* sp., *Streptococcus* sp., *Staphylococcus* sp., *Clostridium* sp., *Listeria monocytogenes*, and *Enterococcus* sp.

Expression of each gene regulated by the T box termination/antitermination complex is dependent on transcription past the leader region termination site; this occurs by stabilization of the antiterminator element by interaction of the leader region of the nascent mRNA of the target gene with a specific class of transfer RNA in the cell. Read-through of the leader region terminator on the nascent mRNA occurs when the charged to uncharged ratio of the corresponding tRNA iso-acceptor is decreased, signaling a deficiency in that aminoacyl-tRNA synthetase or amino acid. (FIG. 5) Sequence comparisons and mutational studies identified a single codon, displayed at a precise position within the leader RNA structure, the "specifier," which determines the specificity of the amino acid response, presumably by pairing with the anticodon of the cognate tRNA (2). As depicted in FIG. 6, the acceptor end of uncharged tRNA apparently makes a second interaction with a bulged region in the antiterminator, based on genetic analyses as well as gel-shift assays using a model 39-nucleotide antiterminator RNA (3, 4); this interaction is proposed to stabilize the antiterminator, preventing the formation of a competing terminator helix (FIG. 7). Mutational studies of the *Bacillus subtilis tyrS* leader and tRNA<sup>Tyr</sup> have indicated that read-through requires additional conserved features of both RNAs (5–7).

Recognition of the tRNA by the leader RNA may mimic recognition by an aminoacyl-tRNA synthetase, which often exploits the anticodon and discriminator positions as specificity determinants (24). As is also true for tRNA charging, the leader RNA–tRNA interaction *in vivo* may involve additional determinants (6, 21). Other systems in which uncharged tRNA is monitored, such as the yeast GCN2 system (25), require a protein component; tRNA mimics such as the *E. coli thrS* regulatory target site are also recognized by a protein (26). In translationally coupled transcription attenuation systems such as the *E. coli trp* operon, tRNA charging is monitored by a translating ribosome (27).

It has previously been established that uncharged tRNA is essential for antitermination; however, it was not known whether other factors are also required to mediate the tRNA–leader interaction. The ability of tRNA<sup>Tyr</sup> mutants to suppress *tyrS* leader mutations provided strong evidence for the role of uncharged tRNA as the effector for transcription antitermination in the T box system (2, 3). However, it was unknown whether the tRNA acted alone or in conjunction with *trans*-acting factors required to mediate the leader RNA–tRNA interaction. As disclosed herein, factor- and ribosome-independent antitermination of the *Bacillus subtilis glyQS* leader is dependent on and specific for tRNA<sup>Gly</sup> and is achieved in a purified *in vitro* transcription system.

Template DNA fragments

Template DNA fragments refers to the polynucleotide used according to the inventions hereof which encodes all or a fragment of a T-box-regulated gene and includes a promoter and the T-box leader, and approximately 30 or more nucleotide residues downstream of the leader region terminator. FIG. 8 shows a map of the *Bacillus subtilis glyQ* promoter and leader regions, which indicates the relative positions of the promoter sequence (including the -35 and -10 regions for recognition by RNAP), the transcription initiation site (position +1), the first several residues of the leader (including the location of the first cytosine residue at +17, which corresponds to the halt location in an assay mixture from which the NTP cytosine triphosphate has been excluded). FIG.1 shows the full leader portion of the *Bacillus subtilis glyQS*, including the specific locations of the specifier and terminator sequences.

A template DNA may include wild-type sequences for the promoter, transcription initiator and leader sequences. Alternatively, one or more of these portions of a template DNA fragment may be a variant of a wild type, or may be a synthetic construct. Specifically, variants of the transcription initiator sequence may be made. For example, according to the present disclosure, variants of the *Bacillus subtilis glyQS* template have been made in which the +2 position (1 nt downstream of the transcription initiation site) is changed from T to C, to allow initiation with the dinucleotide ApC instead of ApU. This is a demonstration that variants of transcription initiator sequence may be used in the assays disclosed herein. Likewise, either or both the specifier and the terminator portions of a wild-type template may be varied to allow the recognition of non-wild type tRNAs. Typically, mutations are introduced into both the specifier and terminator/T-box elements of a leader to alter the specificity of those sequences for tRNA such that the variant forms of the elements recognize a tRNA which is different from that recognized by the wild type specifier and T-box elements. Similarly, the anticodon and discriminator portions of wild type tRNAs may be varied to permit the use of non-wild type tRNAs that will compliment with a wild-type or variant template DNA. Typically, mutations are introduced into both the anticodon and discriminator portions of a tRNA to alter the specificity of those sequences for a leader such that the variant forms of the elements recognize a leader which is different from that recognized by the wild type tRNA anticodon and discriminator. Mutations in leaders and tRNAs may be coordinated such that a wild type leader and its wild type tRNA are both mutated to maintain cognate recognition between the two. Examples are provided herein in the Examples section. Methods for preparing such variants are described herein and are additionally well known in the art.

The portion of the template DNA which is downstream from the terminator of the leader portion is preferably from about 30 to 150 nucleotide residues in length, to allow easy discrimination between the terminated and read-through products in a low resolution polyacrylamide gel electrophoresis system. Read-through products may be measured by alternate methods, e.g., by PCR amplification using an oligonucleotide primer that hybridizes only to the read-through product.

#### Screening for inhibitors of antitermination

Substances which may be inhibitors of bacterial aminoacyl-tRNA synthetase transcription are screened using the disclosed *in vitro* bacterial transcription assay system. The screening process involves the following steps:

a) incubating in parallel two mixtures, each containing a divalent metal cation, NTPs, a dinucleotide (as dictated by the specific transcription initiator sequence in the template DNA), a template DNA fragment containing a promoter, and the leader region of a bacterial gene which is regulated by the T-box mechanism, such as the *B. subtilis glyQS* gene, which encodes glycyl-tRNA synthetase, a bacterial RNA polymerase complex, and a tRNA, such as tRNA<sup>Gly</sup> which is capable of appropriate interaction with the leader sequence, wherein one of the NTPs is excluded from the mixture to permit halting of the complex approximately 10-20 nucleotide residues into the nascent mRNA, and

b) adding to both mixtures the excluded NTP, and adding to only one of the two mixtures a test agent which is a potential inhibitor substance; and

c) comparing the amount of mRNA read-through product produced in the mixture lacking the potential inhibitor with the amount of mRNA read-through product produced in the mixture containing the potential inhibitor. An inhibitor of the antiterminator (i.e., an inhibitor of read-through) will cause a reduction in the amount of mRNA read-through product as compared to the mixture lacking the test agent.

Optionally, the incubation steps (a) and (b) may comprise all four NTPs, in which case, each of the incubations will proceed with transcription elongation immediately following transcription initiation. If the selected NTP is excluded from the initial incubation mixtures, the reactions in each case will be halted at the first encountered residue in the nascent mRNA which codes for the excluded NTP. Preferably, the residue is at residue position 10-50 of the nascent mRNA, and more preferably at residue position 10-20. By excluding a selected NTP which would result in halting within the preferred residue position range, the reactions may be halted for a brief time, by chilling, for example. Thereafter, the conditions may be altered by addition

of other factors or agents, and upon return to appropriate incubation conditions and/or addition of the excluded NTP, elongation of transcription will proceed.

Multiple mixtures may be run in parallel, where one or more of the mixtures serve as appropriate controls, and one or more of the mixtures are used to test a variety of test agents or a range of test agent conditions. Likewise, the incubation mixture may be initially prepared as a large single mixture (bulk mixture) which is thereafter aliquoted into two or more separate mixtures for evaluation of control or test conditions or agents. Preferably, the bulk mixture is a halted complex transcription assay system.

### Examples

#### EXAMPLE 1: *In Vitro* Transcription of *glyQS* mRNA

Bacterial Strains and Growth Conditions. *B. subtilis* strain BR151MA (*lys-3 trpC2*) was used as the source of chromosomal DNA for amplification by PCR. Strains 1A5 (*glyB133 metC3 tre-12 trpC2*; *Bacillus* Genetic Stock Center) and KS115 (*cysA14 hisA1 leuA8 metC3 trpC2*; K. Sandman, Ohio State Univ., Columbus) were used for amino acid limitation experiments for glycine and cysteine, respectively. Cells were propagated in 2X YT medium (9) or in Spizizen minimal medium (10) for measurements of *lacZ* fusion expression. Cells containing *lacZ* fusions were grown in the presence of chloramphenicol at 5 µg/ml.

*In Vitro* Transcription Assays. The template for *glyQS* transcription was a 440-bp PCR fragment that included sequences from 135 bp upstream of the *glyQS* transcription start site to position 305 of the transcript; the termination site is predicted to be around position 220 (ref. 11; FIG. 1; FIG. 12). The template for *tyrS* transcription was a 420-bp PCR fragment including sequences from 85 bp upstream of the transcription start site to position 335 of the transcript; the termination site is predicted to be around position 270 (ref. 12; FIG. 15). PCR products were purified by a Qiagen PCR cleanup kit. Template DNA (10 nM) was incubated in 1X transcription buffer (13) with His-tagged *B. subtilis* RNA polymerase (RNAP) (6 nM) purified as described by Qi and Hulett (14). Halted complex transcription assays were carried out essentially as described by Landick *et al.* (15).

The dinucleotide ApU (150 µM, Sigma) was used to initiate *glyQS* transcription. ATP and GTP were added to 2.5 µM, UTP was added to 0.75 µM, and [alpha-P<sup>32</sup>]UTP (800 Ci/mmol; 1 Ci = 37 GBq) was added to 0.25 µM. Transcription of *glyQS* was initiated in the absence of CTP; for the *glyQS* gene, the first C is at position +17 so that the transcription elongation complex halts after synthesis of 16 nt under these conditions. The dinucleotide ApG was used for initiation of *tyrS* transcription, and GTP was omitted from the initiation reaction, resulting in

a halt at position +11. The initiation reaction mixtures were incubated at 37°C for 15 min and were then placed on ice. Heparin (20 µg/ml, Sigma) was added to block re-initiation, and elongation was triggered by the addition of NTPs to 10 µM final and other reagents as indicated. *B. subtilis* NusA protein (25 nM), purified as described previously (13), was included in the  
5 elongation reaction as indicated. *Escherichia coli* RNAP, prepared as described (16), was used at 10 nM. Transcription reactions were terminated by extraction with phenol, and the products were resolved by denaturing 6% polyacrylamide gel electrophoresis and visualized by Phosphor-Imager analysis.

Unmodified *B. subtilis* tRNA<sup>Gly</sup> and tRNA<sup>Tyr</sup> were made by T7 transcription using a PCR  
10 fragment generated with a 5' oligonucleotide primer that included a T7 promoter sequence, positioned so that the first base of the transcript is the first position of the tRNA, and the final position of the PCR product corresponds to 3' position of the tRNA (FIGS. 13, 16, 17). T7 transcription was carried out by using an Ampliscribe T7 transcription kit (Epicentre Technologies, Madison, WI). The tRNA transcripts were purified on a 6% denaturing  
15 polyacrylamide gel, visualized by using UV shadowing, and eluted into 300 mM NaOAc, pH 4.5/1 mM EDTA. The tRNA was purified by extraction with phenol, precipitated with ethanol, and suspended in water. The resulting tRNA was refolded by incubation at 80°C for 2 min and slow cooling to room temperature before use in the transcription assays at 70 nM. Modified *E. coli* tRNA<sup>Tyr</sup> was purchased from Sigma.

20 Mutations in the *glyQS* template DNA and tRNA<sup>Gly</sup> (as shown in FIG. 10A) were introduced by PCR, using oligonucleotide primers containing the desired alterations.

#### EXAMPLE 2: *Ex vivo* expression of aminoacyl-*glyQS*-synthetase mRNA

β-Galactosidase Measurements. The *glyQS* DNA fragment used for *in vitro* transcription, as described in EXAMPLE 1, was inserted into the *lacZ* fusion vector pFG328 (17) and integrated  
25 in single copy into the *B. subtilis* chromosome by recombination into a bacteriophage SPbeta prophage. Cells were grown in minimal medium containing all required amino acids at 50 µg/ml until mid-exponential growth phase and were then collected and divided into two cultures, containing all required amino acids or with one amino acid at 5 µg/ml. Growth was continued for 4 h, and cells were harvested and assayed for β-galactosidase activity, expressed as Miller units  
30 (9). Glycine starvation experiments were carried out in strain 1A5 (Gly-), and cysteine starvation experiments were carried out in strain KS115 (Cys-). All samples were assayed in duplicate, and growth experiments were carried out at least twice; variation was <10%.

EXAMPLE 3: *In Vitro* tRNA-Directed Antitermination of *glyQS*-aminoacyl-tRNA synthetase mRNA Transcription

In the presence of 30 mM MgCl<sub>2</sub> and low NTP concentrations (10 μM) during the elongation reaction, the *glyQS* leader region terminator was highly efficient (FIG. 9). Addition of a T7 RNAP-generated transcript of *B. subtilis* tRNA<sup>Gly</sup> dramatically increased read-through from 5% (lane 1 or 3) to approximately 60% (lane 2 or 4), with a corresponding decrease in the amount of the terminated transcript. No tRNA-dependent read-through was observed at lower MgCl<sub>2</sub> concentrations or at higher NTP concentrations (data not shown). Mg<sup>2+</sup> plays a crucial role in RNA folding reactions (19) and may facilitate folding of the nascent transcript into the correct conformation for interaction with the tRNA and antitermination. The rate of transcription elongation is decreased at low NTP concentrations (20), which may favor formation of the correct RNA structure or facilitate pausing by RNAP.

Antitermination of the *glyQS* leader responded specifically to tRNA<sup>Gly</sup>; addition of tRNA<sup>Tyr</sup> had no effect (FIG. 9, lane 5). Neither tRNA<sup>Gly</sup> nor tRNA<sup>Tyr</sup> addition increased read-through of the *B. subtilis tyrS* leader region terminator (FIG. 9, lanes 6–11). Therefore, either the *tyrS* and *glyQS* leaders have different requirements for the tRNA–leader interaction or the *tyrS* leader fails to fold properly under the *in vitro* conditions used. The Stem II and Stem IIA/B pseudo-knot elements present in *tyrS* but absent in *glyQS* may be responsible for this difference. Single nucleotide substitutions that disrupt conserved elements of the Stem IIA/B region in the *tyrS* leader result in loss of read-through *in vivo*, indicating that this region is functionally required in the *tyrS* context (5). A variant of the *tyrS* leader in which the specifier sequence and antiterminator were changed to match the anticodon and acceptor end of tRNA<sup>Gly</sup> has been constructed, and expression was shown to be induced *in vivo* in response to limitation for glycine (21). This leader variant failed to respond to tRNA<sup>Gly</sup> *in vitro* (data not shown), indicating that the codon–anticodon interaction (GGC•GCC for *glyQS* vs. UAC•GUA for *tyrS*) is not sufficient to explain the lack of tRNA<sup>Tyr</sup>-directed antitermination of the *tyrS* leader *in vitro*.

EXAMPLE 4: *glyQS* Antitermination *in Vitro* Is Independent of NusA and Functions with *E. coli* RNAP.

The NusA protein affects transcription elongation rates and sensitivity of RNAP to pause and termination sites, and participates in a number of transcription termination control systems, including phage lambda N and Q antitermination (22). Addition of *B. subtilis* NusA to the *glyQS* antitermination reaction resulted in a small increase in termination in the absence of tRNA, especially at high NTP concentrations (ref. 13; data not shown). However, the tRNA<sup>Gly</sup>-



dependent increase in read-through occurred both in the presence and absence of NusA (compare FIG. 9, lanes 1 and 2 with lanes 3 and 4), indicating that NusA is not required for *glyQS* antitermination under these conditions.

The ability of *E. coli* RNAP to replace *B. subtilis* RNAP in the tRNA-dependent transcription antitermination assay was tested to determine whether this activity was sensitive to the source of RNAP. RNAP from *E. coli* and *B. subtilis* has been shown to exhibit different patterns of recognition of pausing and termination signals (ref. 23; unpublished results). *E. coli* RNAP exhibited tRNA<sup>Gly</sup>-dependent read-through similar to that observed with *B. subtilis* RNAP (data not shown), indicating that the antitermination event is dependent on features of the transcript, but not on the enzyme that generates the transcript. Introduction of T box leaders, including *glyQS*, into *E. coli*, from which this antitermination system is absent, generally resulted in a high level of read-through of the leader region terminator independent of amino acid limitation (data not shown), suggesting that the leader region terminators function poorly in the heterologous host and that the proper leader-tRNA interaction does not occur.

EXAMPLE 5: Characterization of Specificity Determinants for Antitermination *in Vitro* and *in Vivo*.

The specificity of the tRNA effect was further tested by using *glyQS* leader variants and corresponding tRNA<sup>Gly</sup> variants (FIG. 10A). The GGC glycine specifier sequence was changed to a UGC cysteine codon, and position A158 of the *glyQS* antiterminator bulge was changed to a U; this position is a secondary determinant of the specificity of the tRNA-leader interaction (3). The mutations were tested separately and in combination, both *in vitro* and *in vivo*. The wild-type *glyQS* template exhibited efficient antitermination *in vitro* only in combination with the corresponding wild-type tRNA<sup>Gly</sup> (FIG. 10B, lane 2). The UGC specifier mutation in the *glyQS* leader resulted in decreased antitermination by wild-type tRNA<sup>Gly</sup>; this effect was suppressed by a variant of tRNA<sup>Gly</sup> with an anticodon complementary to UGC (FIG. 10C, lane 3). The A1583U substitution in the antiterminator also decreased antitermination directed by wild-type tRNA<sup>Gly</sup> and was suppressed by a corresponding change in the tRNA discriminator base (FIG. 10D, lane 4). The specificity pattern also held for the UGC/A1583U double mutant, with the most efficient antitermination occurring in response to the matching tRNA (FIG. 10E, lane 5). The native GGC•GCC codon-anticodon pairing consistently resulted in more efficient antitermination than the UGC•GCA cysteinyl combination; this could be due to the extra G•C pair or to other features of the *glyQS* leader that are adapted to the native glycyl combination.

In agreement with the *in vitro* results, a wild-type *glyQS-lacZ* transcriptional fusion exhibited induction *in vivo* in response to limitation for glycine, but it failed to respond to limitation for cysteine (Table 1). Replacement of the GGC glycine specifier sequence with a UGC cysteine codon resulted in loss of the response to glycine and induction in response to limitation for cysteine; both tRNA<sup>Gly</sup> and tRNA<sup>Cys</sup> contain a U at the discriminator position. The A1583U mutation, either alone or in combination with the UGC cysteine specifier sequence mutation, abolished the response to either glycine or cysteine, consistent with the loss of a match with the U discriminator position. The maximum expression observed under glycine limitation conditions was approximately one-third of that observed in a construct from which the terminator was deleted, indicating that full induction was not observed under these conditions.

Table 1. Expression of *glyQS-lacZ* fusions *in vivo*. Expression was measured by activity of  $\beta$ -galactosidase, in Miller units (9). ND, not determined;  $\Delta$ Term, terminator deleted.

Fusion	Glycine Starvation			Cysteine Starvation		
	+Glycine	-Glycine	Ratio	+Cysteine	-Cysteine	Ratio
GGC-A158	42	130	3.1	34	29	0.85
UGC-A158	58	42	0.72	31	90	2.9
GGC-U158	24	11	0.45	ND	ND	ND
UGC-U158	20	6.0	0.30	14	9.1	0.65
$\Delta$ Term	350	360	1.0	ND	ND	ND

## References

- Henkin, T. M. (2000) *Curr. Opin. Microbiol.* **3**, 149–153.
- Grundy, F. J. & Henkin, T. M. (1993) *Cell* **74**, 475–482.
- Grundy, F. J., Rollins, S. M. & Henkin, T. M. (1994) *J. Bacteriol.* **176**, 4518–4526.
- Gerdeman, M. S., Henkin, T. M. & Hines, J. V. (2002) *Nucleic Acids Res.* **30**, 1065–1072.
- Rollins, S. M., Grundy, F. J. & Henkin, T. M. (1997) *Mol. Microbiol.* **25**, 411–421.
- Grundy, F. J., Collins, J. A., Rollins, S. M. & Henkin, T. M. (2000) *RNA* **6**, 1131–1141.

7. Winkler, W. C., Grundy, F. J., Murphy, B. A. & Henkin, T. M. (2001) *RNA* **7**, 1165–1172.
8. Grandoni, J. A., Fulmer, S. B., Brizzio, V., Zahler, S. A. & Calvo, J. M. (1993) *J. Bacteriol.* **175**, 7581–7593.
- 5 9. Miller, J. H. (1972) *Experiments in Molecular Genetics* (Cold Spring Harbor Lab. Press, Plainview, NY).
10. Anagnostopoulos, C. & Spizizen, J. (1961) *J. Bacteriol.* **81**, 741–746.
11. Kunst, F., Ogasawara, N., Moszer, I., Albertini, A. M., Alloni, G., Azevedo, V., Bertero, M. G., Bessieres, P., Bolotin, A., Borchert, S., Borriss, R., *et al.* (1997) *Nature (London)* **390**, 249–256.
- 10 12. Henkin, T. M., Glass, B. L. & Grundy, F. J. (1992) *J. Bacteriol.* **174**, 1299–1306.
13. Grundy, F. J., Moir, T. R., Haldeman, M. T. & Henkin, T. M. (2002) *Nucleic Acids Res.* **30**, 1646–1655.
14. Qi, Y. & Hulett, F. M. (1998) *Mol. Microbiol.* **28**, 1187–1197.
- 15 15. Landick, R., Wang, D. & Chan, C. L. (1996) *Methods Enzymol.* **274**, 334–353.
16. Hager, D. A., Jin, D. J. & Burgess, R. R. (1990) *Biochemistry* **29**, 7890–7894.
17. Grundy, F. J., Waters, D. A., Allen, S. H. G. & Henkin, T. M. (1993) *J. Bacteriol.* **175**, 7348–7355.
18. Luo, D., Condon, C., Grunberg-Manago, M. & Putzer, H. (1998) *Nucleic Acids Res.* **26**, 5379–5387.
- 20 19. Treiber, D. K. & Williamson, J. R. (2001) *Curr. Opin. Struct. Biol.* **11**, 309–314.
20. Rhodes, G. & Chamberlin, M. J. (1974) *J. Biol. Chem.* **249**, 6675–6683.
21. Grundy, F. J., Hodil, S. E., Rollins, S. M. & Henkin, T. M. (1997) *J. Bacteriol.* **179**, 2587–2594.
- 25 22. Friedman, D. I. & Court, D. L. (2001) *Curr. Opin. Microbiol.* **4**, 201–207.
23. Artsimovitch, I., Svetlov, V., Anthony, L., Burgess, R. R. & Landick, R. (2000) *J. Bacteriol.* **182**, 6027–6035.
24. Giege, R., Sissler, M. & Florentz, C. (1998) *Nucleic Acids Res.* **26**, 5017–5035.

25. Qiu, H., Dong, J., Hu, C., Francklyn, C. S. & Hinnebusch, A. G. (2001) *EMBO J.* **20**, 1425–1438.
26. Sankaranarayanan, R., Dock-Bregeon, A.-C., Romby, P., Caillet, J., Springer, M., Rees, B., Ehresmann, C., Ehresmann, B. & Moras, D. (1999) *Cell* **97**, 371–381.
- 5 27. Landick, R., Turnbough, C. L., Jr., & Yanofsky, C. (1996) in *Escherichia coli and Salmonella: Cellular and Molecular Biology*, eds. Neidhardt, F. C., Curtis, R., III, Ingraham, J. L., Lin, E. C. C., Low, K. B., Magasanik, B., Reznikoff, W. S., Riley, M., Schaecter, A. & Umberger, H. E. (Am. Soc. Microbiol., Washington, DC), pp. 1263–1286.
- 10 28. Ban, N., Nissen, P., Hansen, J., Moore, P. B. & Steitz, T. A. (2000) *Science* **289**, 905–920.
29. Ogle, J. M., Brodersen, D. E., Clemons, W. M., Jr., Tarry, M. J., Carter, A. P. & Ramakrishnan, V. (2001) *Science* **292**, 897–902.
30. Guerrier-Takada, C., Gardiner, K., Marsh, T., Pace, N. & Altman, S. (1983) *Cell* **35**, 849–  
15 857.
31. Weeks, K. M. & Cech, T. R. (1995) *Cell* **82**, 221–230.

## CLAIMS

1. A method for screening substances which are potential inhibitors of transcription of bacterial T-box regulated genes, comprising the steps of:

a) incubating one or more assay mixtures comprising: a template DNA that comprises: (i) a bacterial promoter, (ii) a leader of a T-box regulated gene, including a transcription start site, and (iii) a downstream polynucleotide of sufficient length for detection of a read-through mRNA product; divalent metal cations; nucleoside triphosphates; dinucleotides corresponding to and encoded by the transcription start site of the leader; bacterial RNA polymerase complex; and tRNA specific for a specifier sequence located in the leader; and

b) incubating a potential inhibitor substance with one or more assay mixtures comprising: a template DNA that comprises: (i) a bacterial promoter, (ii) a leader of a T-box regulated gene, including a transcription start site, and (iii) a downstream polynucleotide of sufficient length for detection of a read-through mRNA product; divalent metal cations; nucleoside triphosphates; dinucleotides corresponding to and encoded by the transcription start site of the leader; bacterial RNA polymerase complex; and tRNA specific for a specifier sequence located in the leader; and

c) comparing the amount of the read-through mRNA product produced in step a) with the amount the read-through mRNA product produced in step b)

wherein a lesser amount of a read-through mRNA product determined for step b) in comparison with step a) indicates that said potential inhibitor substance inhibits transcription of said T-box regulated gene.

2. The method recited in claim 1 wherein the divalent metal cation is  $Mg^{2+}$ .

3. The method recited in claim 1 wherein the nucleoside triphosphates are selected from the group consisting of adenosine triphosphate, guanosine triphosphate, cytosine triphosphate, and uridine triphosphate, and any combination of one or more of these.

4. The method recited in claim 1 wherein the dinucleotides are selected from the group consisting of ApA, ApC, ApU, ApG, GpA, GpC, GpU, GpG, CpA, CpC, CpU, CpG, UpA, UpC, UpU, and UpG.

5. The method recited in claim 1 wherein the bacterial promoter is selected from the group consisting of the *B. subtilis glyQS* promoter and the *B. subtilis rpsD* promoter.

6. The method recited in claim 1 wherein the downstream polynucleotide of sufficient length for detection of a read-through mRNA product comprises a polynucleotide which is from about 30 to 150 nucleotide residues in length.

7. The method recited in claim 1 wherein the tRNA specific for a specifier sequence located in the leader is *B. subtilis* tRNA<sup>Gly</sup>.

8. The method recited in claim 1 wherein the RNA polymerase is from either *B. subtilis* or *Escherichia coli*.

9. The method recited in claim 1 wherein the leader comprises a polynucleotide which is a variant of a wild-type glycine synthetase leader from a Gram positive bacterial strain, wherein the variant comprises modifications to one or both of the wild-type specifier and wild-type terminator sequences.

10. The method recited in claim 1 wherein the tRNA specific for a specifier sequence located in the leader is a variant of a wild-type tRNA wherein any one or more of the wild-type anticodon sequence, the wild-type discriminator sequence, and the transcription start site is altered to complement with the leader sequence.

11. The method recited in claim 1 wherein the leader comprises a polynucleotide which is a variant of a wild-type glycine synthetase leader sequence from a Gram positive bacterial strain, wherein the variant comprises modifications to one or both of the wild-type specifier and wild-type terminator sequences, and wherein the tRNA specific for a specifier sequence located in the wild-type leader is a variant of a wild-type tRNA wherein either or both of the wild-type anticodon sequence and the wild-type discriminator sequence are altered to complement with the variant leader sequence.

12. The method recited in claim 1 wherein the assay mixtures are *in vitro* halted-complex bacterial transcription assay systems.

13. A method for identifying inhibitors of transcription of bacterial T-box regulated genes, comprising:

providing two or more *in vitro* halted-complex bacterial transcription assay systems which comprise a template DNA comprising: (i) a bacterial promoter, (ii) a polynucleotide comprising a portion of a leader from the *B. subtilis glyQS* gene and includes a transcription start site, and (iii) a downstream polynucleotide of sufficient length for detection of a read-through mRNA product; RNA polymerase, and uncharged *B. subtilis* tRNA<sup>Gly</sup>, wherein at least one or more of said assay systems comprises a test substance, and wherein at least one or more of said assay systems lacks a test substance, and comparing the amount of *B. subtilis glyQS* read-through mRNA produced in each of said assay systems, wherein a test substance is considered an inhibitor if it effects a lesser amount of *B. subtilis glyQS* read-through mRNA produced in an

assay system comprising such test substance as compared to an assay system lacking any test substance.

14. The method recited in claim 13 wherein the bacterial promoter is selected from the group consisting of the *B. subtilis glyQS* promoter and the *B. subtilis rpsD* promoter.

15. The method recited in claim 14 wherein the RNA polymerase is from either *B. subtilis* or *Escherichia coli*.

16. The method recited in claim 13 wherein the sequence of the polynucleotide comprising a portion of the *B. subtilis glyQS* leader is a variant of the wild-type *B. subtilis glyQS* leader sequence, wherein the variant comprises modifications to one or both of the wild-type specifier and wild-type antiterminator sequences.

17. The method recited in claim 13 wherein the uncharged *B. subtilis* tRNA<sup>Gly</sup> is a variant of a wild-type *B. subtilis* tRNA<sup>Gly</sup> wherein either or both the wild-type anticodon sequence and the wild-type discriminator sequence is altered to complement with the *B. subtilis glyQS* polynucleotide leader region.

18. An assay system for screening substances which are potential inhibitors of transcription of bacterial T-box regulated genes, comprising:

a) one or more assay mixtures comprising: a template DNA that comprises: (i) a bacterial promoter, (ii) a leader of a T-box regulated gene, including a transcription start site, and (iii) a downstream polynucleotide of sufficient length for detection of a read-through mRNA product; divalent metal cations; nucleoside triphosphates; dinucleotides corresponding to and encoded by the transcription start site of the leader; bacterial RNA polymerase complex; and tRNA specific for a specifier sequence located in the leader; and

b) one or more assay mixtures comprising: a potential inhibitor substance; a template DNA that comprises: (i) a bacterial promoter, (ii) a leader of a T-box regulated gene, including a transcription start site, and (iii) a downstream polynucleotide of sufficient length for detection of a read-through mRNA product; divalent metal cations; nucleoside triphosphates; dinucleotides corresponding to and encoded by the transcription start site of the leader; bacterial RNA polymerase complex; and tRNA specific for a specifier sequence located in the leader.

19. The assay system recited in claim 18 wherein the divalent metal cation is Mg<sup>2+</sup>.

20. The assay system recited in claim 18 wherein the nucleoside triphosphates are selected from the group consisting of adenosine triphosphate, guanosine triphosphate, cytosine triphosphate, and uridine triphosphate, and any combination of one or more of these.

21. The assay system recited in claim 18 wherein the dinucleotides are selected from the group consisting of ApA, ApC, ApU, ApG, GpA, GpC, GpU, GpG, CpA, CpC, CpU, CpG, UpA, UpC, UpU, and UpG.

22. The assay system recited in claim 18 wherein the bacterial promoter is selected from the group consisting of the *B. subtilis glyQS* promoter and the *B. subtilis rpsD* promoter.

23. The assay system recited in claim 18 wherein the downstream polynucleotide of sufficient length for detection of a read-through mRNA product comprises a polynucleotide which is from about 30 to 150 nucleotide residues in length.

24. The assay system recited in claim 18 wherein the tRNA specific for a specifier sequence located in the leader is *B. subtilis* tRNA<sup>Gly</sup>.

25. The assay system recited in claim 18 wherein the RNA polymerase is from either *B. subtilis* or *Escherichia coli*.

26. The assay system recited in claim 18 wherein the leader comprises a polynucleotide which is a variant of a wild-type glycine synthetase leader from a Gram positive bacterial strain, wherein the variant comprises modifications to one or both of the wild-type specifier and wild-type terminator sequences.

27. The assay system recited in claim 18 wherein the tRNA specific for a specifier sequence located in the leader is a variant of a wild-type tRNA wherein any one or more of the wild-type anticodon sequence, the wild-type discriminator sequence, and the transcription start site is altered to complement with the leader sequence.

28. The assay system recited in claim 18 wherein the leader comprises a polynucleotide which is a variant of a wild-type glycine synthetase leader sequence from a Gram positive bacterial strain, wherein the variant comprises modifications to one or both of the wild-type specifier and wild-type terminator sequences, and wherein the tRNA specific for a specifier sequence located in the wild type leader is a variant of a wild-type tRNA wherein either or both of the wild-type anticodon sequence and the wild-type discriminator sequence are altered to complement with the variant leader sequence.

29. The assay system recited in claim 18 wherein the assay mixtures are *in vitro* halted-complex bacterial transcription assay systems.

30. An assay system for identifying inhibitors of transcription of bacterial T-box regulated genes, comprising:



two or more *in vitro* halted-complex bacterial transcription assay systems which comprise a template DNA comprising: (i) a bacterial promoter, (ii) a polynucleotide comprising a leader from the *B. subtilis* *glyQS* gene, including a transcription start site, and (iii) a downstream polynucleotide of sufficient length for detection of a read-through mRNA product; RNA polymerase, and uncharged *B. subtilis* tRNA<sup>Gly</sup>, wherein at least one or more of said assay systems comprises a test substance, and wherein at least one or more of said assay systems lacks a test substance.

31. The assay system recited in claim 30 wherein the bacterial promoter is selected from the group consisting of the *B. subtilis* *glyQS* promoter and the *B. subtilis* *rpsD* promoter.

32. The assay system recited in claim 30 wherein the RNA polymerase is from either *B. subtilis* or *Escherichia coli*.

33. The assay system recited in claim 30 wherein the sequence of the polynucleotide comprising a portion of the *B. subtilis* *glyQS* leader is a variant of the wild-type *B. subtilis* *glyQS* leader sequence, wherein the variant comprises modifications to one or both of the wild-type specifier and wild-type terminator sequences.

34. The assay system recited in claim 30 wherein the uncharged *B. subtilis* tRNA<sup>Gly</sup> is a variant of a wild-type *B. subtilis* tRNA<sup>Gly</sup> wherein either or both the wild-type anticodon sequence and the wild-type discriminator sequence is altered to complement with a polynucleotide encoding a variant *B. subtilis* *glyQS* leader.

35. A method for manufacturing an antibiotic agent, comprising:

Screening one or more test agents which are potential inhibitors of expression of T-box regulated genes by the following steps:

a) incubating one or more assay mixtures comprising: divalent metal cations; nucleoside triphosphates; dinucleotides; a template DNA that comprises: (i) a bacterial promoter, (ii) a leader of a T-box regulated gene, and (iii) a downstream portion; a bacterial RNA polymerase complex; and tRNA specific for a specifier sequence located in the leader portion of the template DNA; and

b) incubating a test substances with one or more assay mixtures comprising: a divalent metal cation; nucleoside triphosphates; dinucleotides; a template DNA comprising a bacterial promoter, the leader region of a T-box regulated gene, and a downstream portion; a bacterial RNA polymerase complex; and tRNA specific for a specifier sequence located in the leader portion of the template DNA; and

c) comparing the amount of the read-through mRNA product produced in step a) with the amount the read-through mRNA product produced in step b)

wherein a lesser amount of a read-through mRNA product determined for step b) in comparison with step a) indicates that said test agent inhibits transcription of T-box regulated genes and is an antibiotic agent.

5

Producing for use as antibiotic agents those test agents which inhibit production of a read-through mRNA product.

FIG. 1




FIG. 2




FIG. 3: Panel A

B. sub tyrs AGCTTCATATGAAAGGTAAGATTGACA--CAAGTAGA-ATATCTT-TACCT-----TCCAGAGA-GCT---GAT  
 B. ant glys ATTATTAATATAAGTAGCGATGACGGACT-TATAGTACTTGC-ACA-----AAAAGCGA-TTC---AGG  
 B. cer glys ATTATTAATATAAGTAGCGATGACGGACT-TATAGTACTTGC-ACA-----AAAAGCGA-TTC---AGG  
 B. hal glys AATGTTATATTTCATGCTATGACGGACA--ACAGTACTTGAATCCCT-TTTACAT-----AAAAGCGA-ACC---TAG  
 B. ste glys AAATCATATATGATCGCGATGACGGACTC-AATAGTAGTTAACCTTC-TCTTC-----CCAGCGA-GCC---GGG  
 B. sub glys TATTATTAAATATGTTGCAGTGAGAGAAA--GAAGTACTTGGTTTA-CCTCAT-----GAAAGCGA-CCT---TAG  
 C. ace glys ATAAATTTAATATCTATACATGACAAATAT---AGAAATGTATTTT-CCT-----CAAAGAGA-GGC---TGT  
 C. hyd glys AATTAATAATGATGGATGGCAGTGAACCTGCA--GGAGTACCG-AGAAGA-CCCT-----TAAAGAGA-GCC---GGG  
 D. rad glys GAGAGTTTTAAATACGTACGAGAGAAA--GAAGTACCG-AGAAGA-GGCCCA-----ACGAGCGA-GCC---TGA  
 E. fae glys GCCTTGACAAAATGGGAAAATAGAGCTAG--GAAGTAAAGAAACCC-TCTGTT-----AAGCGAA-TCT---GG  
 L. lac glys ATATCAACTAATAGTACGTTGAAGAAA-ATAGTAAACAAGCT-CT-AT-----AGCGA-CTC---GAA  
 L. mon glys ATGTCACAAACACATTAATTTACTTGC-TTTAAATAATCTATCAA-TT-----\*GTACAGCGA-GTT---AAG  
 S. aur glys TTGTGTATAAACTAACCAATAG-CAACA-----AAATAGCAGG-TTCTGATC-----TAAAGCGA-GCT---CGG  
 S. equ glys -----GTTAAGAAA-AGGT-TTGT-----GGCGTTTC-TGCAGCGA-ACC---TGA  
 S. mut glys ATTTTGTATATAATAGTCAGCAGGAAAGA-AGTCTT-AT-----GGCGTTTC-TCAAGCGA-GCT---TGG  
 S. pne glys GCTTTATGCTAACTAGACTCTAGAAA-AGATGCAAG-----TATCTTATC-----TAAAGCGA-GTT---CGG  
 S. pyo glys

FIG. 3: Panel B

B. sub tyrs ---GGCCGGTGAAA-ATC--AGCACAGA-----CGGATATATC-GAA---TACA-CTCATGAACC-----  
 B. ant glys ---GATAGTGAAAG-CCT---GAAGCC-----GCAAG-GAA-ACGGCA-GTCTCGAGC-----  
 B. cer glys ---GATAGTGAAAG-CCT---GAAGCC-----GCAAG-GAA-ACGGCA-GTCTCGAGC-----  
 B. hal glys ---GATGTGAGAG-CTA--GGATGTAAA-----CATCAAG-GAA--GGCA-CTTTGAGCA-TGAA-----  
 B. ste glys ---GACGGTGAAG-CCC--GGCAAGA-----TGTTAAT-GAA-ACGGCA-GTCTCGAGC-----  
 B. sub glys ---GGCGGTGAAG-CTA--AGGATGAG-----CACGCAAC-GAA-ACGGCA-TTCTTGAGCAA-----  
 C. ace glys ---GGAGGGGTGTA--ACG--GTCAAG-----AAATTCAGT-AGT---GGAG-TCTTTCAGTA-----  
 C. hyd glys ---GGCTGGTGTGA--ACC--GGTAGGG-----A-TAAACGCT-GAA--GGCG-CCGEGGAGCC-----  
 D. rad glys ---GACGGTGAAG-TCA--GGCAGGGTGA--GGCGGACGG-GAA--AGGCA-CCGEGGAGCC-----  
 E. fae glys ---GAGAGTGGAG-CC--AGAAACA-----CAGAACTTT-GAA-AGGCA-CTTTGGAGTACG-----  
 L. lac glys ---GATAGTGAAAG-TTC--GAGAAC-----AATAA-T-----GGCT-TAAT-----  
 L. mon glys ---GTTGGTGTGAG-CCG--GATATTTA-ACITTTTCT-GAA--GGCG-TTCTGGAGTA-----  
 S. aur glys ---GATAGTGAAG-CTT--AACA-----T--AAGATT-----GGC--CTAACGAATC-----  
 S. equ glys ---GGCTGGTGAAG-CCG--AGTGAT-GG--T-----ACTGCTGGTT-----GGCG-CTTCTCTA-----  
 S. mut glys ---GAGAGTGAAG-TCA--GGTAAACAAA-ATAAGGACT-----ATTAAGGACT-----GGCA-CTTTCT-----  
 S. pne glys ---GATAGTGGAG-CCA--AGTAGGGCAA-ATAAGGGCT-----ATAAGGGCT-----GGCG-CTTTCT-----  
 S. pyo glys ---GATAGTGAAG-CCG--AATGTAGGA-CTGAGAGT-----GGCG-CTTCTGGTT-----

FIG. 3: Panel C

B. sub <u>tyrs</u>	GCT	TTTGC	AAAC	AAAGCC	GGCCA	GGCTTT	CAGTA	GTGAA	AGA
B. ant <u>glys</u>					AAATACGTGATAA				
B. cer <u>glys</u>					AAATACGTGATAA				
B. hal <u>glys</u>					CGATGAAAAGAA				
B. ste <u>glys</u>					GAAATGGCAAAA				
B. sub <u>glys</u>									
C. ace <u>glys</u>	TTT	TT		AAAA	CAAG	GGG	AGTAAAGCC	GA	AAA
C. hyd <u>glys</u>	GCA	GGAGGAAA	CCC						TGC
D. rad <u>glys</u>									
E. fae <u>glys</u>									
L. lac <u>glys</u>									
L. mon <u>glys</u>									
S. aur <u>glys</u>									
S. equ <u>glys</u>									
S. mut <u>glys</u>	CTT	GGCT		AAT			AGCC		AAG
S. pne <u>glys</u>									
S. pyo <u>glys</u>	GGG	CAGTGT	GATTAAG	TATA				TTT	GTCAATATTTG
									CCC

FIG. 3: Panel D

B. sub <u>tyrs</u>	ACGGA	CCTGA	TCGGTTATCAGG	
B. ant <u>glys</u>				
B. cer <u>glys</u>				
B. hal <u>glys</u>				
B. ste <u>glys</u>				
B. sub <u>glys</u>				
C. ace <u>glys</u>	GC	AGG	GCTATTGCC	
C. hyd <u>glys</u>				
D. rad <u>glys</u>				
E. fae <u>glys</u>				
L. lac <u>glys</u>				
L. mon <u>glys</u>				
S. aur <u>glys</u>				
S. equ <u>glys</u>				
S. mut <u>glys</u>				
S. pne <u>glys</u>				
S. pyo <u>glys</u>				

FIG. 3: Panel E

B. sub tyrs ----- AAAGTGA ----- TAAGACGAATGTTG ----- CATTG-TCTTA ----- TTA  
 B. ant glys ----- AGTGGAT ----- GCACCTTTT ----- GTGT ----- ATC  
 B. cer glys ----- AGTGGAT ----- GCACCTTTT ----- GTGT ----- ATC  
 B. hal glys ----- AGTGGC ----- TATGGTGC ----- ATCATA ----- GGC  
 B. ste glys ----- AGGGAT ----- GCGTGAT ----- TGCGC ----- ATC  
 B. sub glys ----- TTTTAAAAAGAGGCT ----- GGGATTTTGT ----- TCTC ----- AGC  
 C. ace glys -----  
 C. hyd glys ----- AGAGTTTGTAGGTGGC ----- CTTTTT ----- G ----- GCC  
 D. rad glys ----- ACAACCGTCTGAAAGGTGCTG ----- GCGAGG ----- GC ----- CAG  
 E. fae glys ----- ----- GCCGATGAACA ----- CATCGG ----- AAG  
 L. lac glys -----  
 L. mon glys ----- GGTGGGA ----- ATTGTTT ----- TAAT ----- TCC  
 S. aur glys ----- AGCGAGT ----- GACTA ----- C ----- ACT  
 S. equ glys ----- GGTGTTT ----- GTAGCTTGCTTGACATCTGTT ----- TATCAA-CAAG-ATC ----- AAA  
 S. mut glys ----- CTACA ----- ATCAGATAAA ----- TGA ----- AGT  
 S. pne glys ----- GTAGTAT ----- T-TTCAAAACAA ----- TGAAGTA ----- ATA  
 S. pyo glys ----- AAAAAGATAC ----- TATATAAA ----- TGAA ----- GTA

FIG. 3: Panel F

B. sub tyrs ----- GTAGGGTGGTACCGCGAT ----- AATCA ----- ATCGT ----- CCTT  
 B. ant glys ----- AACTAGGTGGAAACCGCGGC ----- AAAC ----- GCTCGT ----- CCTAG-  
 B. cer glys ----- AACTAGGTGGAAACCGCGGC ----- AAAC ----- GCTCGT ----- CCTAG-  
 B. hal glys ----- AACTAGGTGGAAACCGCGG ----- TTAAC ----- CTCTG ----- CCTAT-  
 B. ste glys ----- AACTAGGTGGAAACCGCGGAC ----- TAC ----- GCTCTCGT ----- CCTAG-  
 B. sub glys ----- AACTAGGTGGAAACCGCGGGA ----- GAAC ----- TCTCGT ----- CCTA-  
 C. ace glys ----- AATAAGGTGGAAACCGCGGAA ----- GTAA ----- TTTCTG ----- CCTT-  
 C. hyd glys ----- AACCCAGGTGGAAACCGCGGAGG ----- ATGC ----- CCTTCTG ----- CCTTGG-  
 D. rad glys ----- AACTGGGTGGAAACCGCGCATG ----- TCC ----- CGTGGT ----- CCGCG-  
 E. fae glys ----- TAGGGTGGAAACCGCGGA ----- TAATTAT ----- TCGT ----- CCTA-  
 L. lac glys ----- ATAAAGGTGGAAACCGTGC ----- ATTT ----- GCAC ----- CTTTGT  
 L. mon glys ----- AATAGGTGGAAACCGCGAG ----- CTAAC ----- CTCTG ----- CCTAT-  
 S. aur glys ----- AATTGGGTGGAAACCGCGGTT\* ----- TTG ----- AACTCTG ----- CCTA-  
 S. equ glys ----- TGAAGTAATAATAGGTGGAAACCGCGT ----- TCA ----- AAGC ----- CCTA-  
 S. mut glys ----- AATAAATTAGGTGGAAACCGGTT ----- TCA ----- AAGC ----- CCTA-  
 S. pne glys ----- AATTAGGTGGAAACCGGTT ----- TCT ----- GAGC ----- CCTAG-  
 S. pyo glys ----- ATAAATTAGGTGGAAACCGCGT ----- TTG ----- ACGC ----- CCTAG-

## FIG. 4

**ORGANISMS WITH LEADER SEQUENCES HAVING THE T BOX PATTERN**  
**NCBI GENOME SEQUENCE FILE NAME**

<i>Bacillus anthracis</i>	NC_003997
<i>Bacillus cereus</i>	NC_004722
<i>Bacillus halodurans</i>	NC_002570
<i>Bacillus subtilis</i>	NC_000964
<i>Carboxydotherrnus hydrogenofomans</i>	NC_002972
<i>Clostridium acetobutylicum</i>	NC_003030
<i>Clostridium botulinum</i>	NC_003223
<i>Clostridium difficile</i>	NC_002933
<i>Clostridium perfringens</i>	NC_003366
<i>Clostridium tetani</i>	NC_004557
<i>Clostridium thermocellum</i>	NZ_AABG000000000
<i>Corynebacterium glutamicum</i>	NC_003450
<i>Corynebacterium diptheriae</i>	NC_002935
<i>Deinococcus radiodurans</i>	NC_001263
<i>Desulfitobacterium hafniense</i>	NZ_AAAW000000000
<i>Enterococcus faecalis</i>	NC_004668
<i>Enterococcus faecium</i>	NZ_AAAK000000000
<i>Geobacillus stearothermophilus</i>	NC_002926
<i>Geobacter sulfurreducens</i>	NC_002939
<i>Lactococcus lactis</i>	NC_002662
<i>Leuconostoc mesenteroides</i>	NZ_AABH000000000
<i>Listeria innocua</i>	NC_003212
<i>Listeria monocytogenes</i>	NC_003210
<i>Mycobacterium leprae</i>	NC_002677
<i>Mycobacterium tuberculosis</i>	NC_000962
<i>Oceanobacillus iheyensis</i>	NC_004193
<i>Oenococcus oeni</i>	NZ_AAAAZ000000000
<i>Ruminococcus albus</i>	NC_003373
<i>Spiroplasma kunkelii</i>	NC_003999
<i>Staphylococcus aureus</i>	NC_002758
<i>Staphylococcus epidermidis</i>	NC_004461
<i>Streptococcus equi</i>	NC_002955
<i>Streptococcus gordoniae</i>	NC_002979
<i>Streptococcus mutans</i>	NC_004350
<i>Streptococcus pneumoniae</i>	NC_003098
<i>Streptococcus pyogenes</i>	NC_002737
<i>Streptomyces coelicolor</i>	NC_003888
<i>Thermoanaerobacter tengcongensis</i>	NC_003869
<i>Thermobifida fusca</i>	NZ_AAAQ000000000



FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9





FIG. 10



## FIG. 11

Polynucleotide sequence for the *glyQS* gene from *Bacillus subtilis* corresponding to the *in vitro* transcription template: from *B. subtilis* 168.

ATTGATTTATATTACGAAGAATATTCGGGATTGTATTTAAATCAAAGCGCTTTTAGATCAAATGGAAAGCATG  
AAACATCTTATGGGTGAAAACAAAAGTTGACATTTGGTCCATCTTTTATATGATCATTATTATTAAATATGTT  
GCAGTGAGAGAAAGAAGTACTTGCGTTTACCTCATGAAAGCGACCTTAGGGCGGTGTAAGCTAAGGATGAGCACG  
CAACGAAAGGCATTCTTGAGCAATTTAAAAAAGAGGCTGGGATTTTGTTCAGCAACTAGGGTGGAACCGCGG  
GAGAACTCTCGTCCCTATGTTTGCGGCTGGCAAGCATAGAGACGGGAGTTTTTTGGTTGCTGCCGCAGTCAACTT  
ATGAAAGAAAAGTGGAGGTGCTTGAAATGAATATTCAAGACATGATTCTAACCTTGCAAAAGC

## FIG. 12

Sequence of same region from BR151MA (T to A at +6 position relative to transcription start-site)

```
ATTGATTTATATTACGAAGAATATTCGGGATTGTATTTAAAATCAAAGCGCTTTTATAGATCAAATGGAAAGCATG
AAACATCTTATGGGTGAAAACAAAAGTTGACATTTGGTCCATCTTTTATATGATCATTATTATAAAATATGTT
GCAGTGAGAGAAAGAAGTACTTGCGTTTACCTCATGAAAGCGACCTTAGGGCGGTGTAAGCTAAGGATGAGCACG
CAACGAAAGGCATTCTTGAGCAATTTTAAAAAAGAGGCTGGGATTTTGTTCAGCAACTAGGGTGGAAACCGCGG
GAGAACTCTCGTCCCTATGTTTGCGGCTGGCAAGCATAGAGACGGGAGTTTTTTGGTTGCTGCCGCAGTCAACTT
ATGAAAGAAAAGTGGAGGTGCTTGAAATGAATATTCAAGACATGATTCTAACCTTGCAAAGC
```



## FIG. 13

tRNA<sup>Gly</sup> DNA sequence: (from SubtiList, confirmed by sequencing of region in BR151MA)

GCGGAAGTAGTTCAGTGGTAGAACACCACCTTGCCAAGGTGGGGGTCGCGGGTTCGAATCCCGTCTTCCGCTCCA

## FIG. 14

PCR primers used for preparing *glyQS* template:

GlyQUS1Xba: ATTGATCTAGATTACGAAGAATATTCGGGATTGTA (contains two changes from sequence shown in Fig. 12 to introduce an XbaI site (TCTAGA) at the 5' end of the fragment for generation of the *glyQS-lacZ* fusion construct)

GlyQDS2H3Pac: GGGTATTTAATTAAGCTTTTGCAAGGTTAGAATCA (introduces extra 14 nt downstream of *glyQS* sequence shown in Fig. 12 to provide a HindIII site (AAGCTT) for generation of the *glyQS-lacZ* fusion construct)

The PCR primers used to generate the *tyrS* template:

TyrUSBM: GGCTGGGGATCCGTCAACAATGGAGG

TyrN2b: CCGCGGAAGGATAAAGCTTCAAGTAAG

## FIG. 15

Polynucleotide sequence for the *tyrS* template DNA (identical for 168 or BR151MA).

GGCTGGAGATCTGTCAACAATGGAGGATTAAAAGGCGGCGTTGACACAGGATTTTATTTATGTTAAAAATGATAT  
AGCTTCATATGAAAAGGTAAAGATTGAGACAAGTAGAATATCCTTACGTTCCAGAGAGCTGATGGCCGGTGAAAA  
TCAGCACAGACGGATATATCGAATACACTCATGAACCGCTTTTGCAAACAAAGCCGGCCAGGCTTTCAGTAGTGA  
AAGAACGGACCTGATCCGTTATCAGGCAAAGTGATAAGACGAATGTTTGCATTCTCTTATTAGTAGGGTGGTACC  
GCGATAATCAATCGTCCCTTCGTGTAAACGAAGGGGCGTTTTTTATTTTAATTAAAAAAGGAGCTTTATCTTATG  
ACTAACTTACTTGAAGACTTATCCTTCCGCGG

## FIG. 16

The oligos used to generate tRNA<sup>Tyr</sup>:

5': TyrUSBM: GGCTGGGGATCCGTCAACAATGGAGG  
3': TyrN2b: CCGCGGAAGGATAAAGCTTCAAGTAAG

5': tRNATyrUST7: TAATACGACTCACTATAGGAGGGGTAGCG (the tRNA sequence starts with GGAGGGGTAGCG)  
3': tRNATyrDS: TGGTGGAGGGGGCAGATTCG

The oligos used to generate tRNA<sup>Gly</sup>:

5': GlytRNAUS: TAATACGACTCACTATAGCGGAAGTAGTTCAGTGG  
(the first part of this oligo is the T7 promoter; the tRNA starts with GCGGAAGTAGTTCAGTGG)  
3': GlytRNADS: TGGAGCGGAAGACGGGATTCGAAC

## FIG. 17

tRNA<sup>Tyr</sup> DNA sequence.

GGAGGGGTAGCGAAGTGGCTAAACGCGGCGGACTGTAAATCCGCTCCCTCAGGGTTCGGCAGTTCGAATCTGCCC  
CCCTCCACCA